An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
a study on Fibrodysplasia Ossificans Progressiva
Fibrodysplasia Ossificans Progressiva Open-label extension study Clinical trial Phase 2 Efficacy and safety Heterotopic ossification Flare-up Palovarotene Retinoic acid receptor agonist Retinoic acid receptor gamma agonist Clementia Myositis Ossificans Progressiva Munchmeyer's Disease FOP Ipsen Myositis Ossificans Palovarotene dose level 1 Palovarotene dose level 2 Palovarotene dose level 3 Palovarotene dose level 4
Lead Scientist at UCSF
- Edward Hsiao
Professor, Medicine. Authored (or co-authored) 91 research publications.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Clementia Pharmaceuticals Inc.
- Website for the International FOP Association Website for the French FOP Association more information about this study: A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossificans Progressiva (FOP)
- Phase 2
- Study Type
- Last Updated